2-tur qandli diabet va semizlikda glp-1 asosidagi davolash usullari: zamonaviy dalillar, kardiorenal foydalar, xavfsizlik va istiqbollar
Аннотация
2-tur qandli diabet (2TQD) va semizlik o‘zaro chambarchas bog‘liq bo‘lgan surunkali metabolik kasalliklar bo‘lib, yurak-qon tomir tizimi hamda buyraklar asoratlari xavfini sezilarli oshiradi. Glyukagonsimon peptid-1 retseptori agonistlari (GLP-1 RA) va yangi inkretin asosidagi preparatlar endokrinologiyada davolash maqsadlarini faqat glikemiyani pasaytirish va tana vaznini kamaytirish bilan cheklamay, ayrim bemor guruhlarida yurak-qon tomir xavfini kamaytirish va buyrak faoliyatini himoya qilish yo‘nalishlariga ham kengaytirdi. Ushbu narrativ sharhda GLP-1 asosidagi davolashning fiziologik mexanizmlari, glikemik va vazn kamaytiruvchi samaradorligi, yurak-qon tomir va buyrak natijalari bo‘yicha klinik dalillar, xavfsizlik jihatlari hamda 2TQD va semizlikni individual boshqarishdagi amaliy tamoyillar umumlashtiriladi. Yirik klinik natijalar tadqiqotlari va zamonaviy xalqaro tavsiyalar tahlil qilinadi. Bemor tanlash, dozani bosqichma-bosqich oshirish, gastrointestinal nojo‘ya ta’sirlar, qarshi ko‘rsatmalar va ehtiyot choralari, homiladorlik davridagi yondashuv hamda natriy-glyukoza kotransporteri-2 (SGLT2) ingibitorlari bilan birgalikda qo‘llash masalalariga alohida e’tibor qaratiladi. Preparatlar o‘rtasidagi farqlar, tadqiqot populyatsiyalari va kuzatuv muddatlari bir xil emasligi sababli, klinik natijalarni har bir preparat va bemor guruhiga mos talqin qilish zarurligi ta’kidlanadi. GLP-1 asosidagi preparatlar ovqatlanish, jismoniy faollik, arterial bosim va lipidlar nazorati kabi kompleks choralarni almashtirmaydi, balki ular bilan birgalikda qo‘llanadigan uzoq muddatli davolash strategiyasining bir qismi hisoblanadi.
Kalit so‘zlar: 2-tur qandli diabet, semizlik, GLP-1 retseptori agonistlari, inkretin terapiyasi, semaglutid, tirzepatid, yurak-qon tomir natijalari, surunkali buyrak kasalligi, metabolik endokrinologiya
Библиографические ссылки
1. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1). https://diabetesjournals.org/care/issue/48/Supplement_1
2. American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1). https://diabetesjournals.org/care/issue/48/Supplement_1
3. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and the EASD. Diabetes Care. 2022;45(11):2753–2786. https://doi.org/10.2337/dci22-0034
4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5S):S1–S127. https://doi.org/10.1016/j.kint.2022.06.008
5. American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1). https://diabetesjournals.org/care/issue/48/Supplement_1
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205–216. https://doi.org/10.1056/NEJMoa2206038
7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016;375:311–322. https://doi.org/10.1056/NEJMoa1603827
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375:1834–1844. https://doi.org/10.1056/NEJMoa1607141
9. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). The Lancet. 2019;394:121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
10. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389:2221–2232. https://doi.org/10.1056/NEJMoa2307563
11. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. 2024;391:109–121. https://doi.org/10.1056/NEJMoa2403347
12. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020;383:1436–1446. https://doi.org/10.1056/NEJMoa2024816
13. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия

Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.

